| Personalized cancer vaccines: clinical landscape, challenges, and opportunities CS Shemesh, JC Hsu, I Hosseini, BQ Shen, A Rotte, P Twomey, S Girish, ... Molecular Therapy 29 (2), 555-570, 2021 | 169 | 2021 |
| Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1–2 study B Geoerger, CM Zwaan, LV Marshall, J Michon, F Bourdeaut, ... The Lancet Oncology 21 (1), 134-144, 2020 | 120 | 2020 |
| Disposition and pharmacology of a GalNAc3-conjugated ASO targeting human lipoprotein (a) in mice ZY Rosie, MJ Graham, N Post, S Riney, T Zanardi, S Hall, J Burkey, ... Molecular Therapy-Nucleic Acids 5, 2016 | 89 | 2016 |
| Indocyanine green loaded liposome nanocarriers for photodynamic therapy using human triple negative breast cancer cells CS Shemesh, CW Hardy, SY David, B Fernandez, H Zhang Photodiagnosis and Photodynamic Therapy 11 (2), 193-203, 2014 | 82 | 2014 |
| Thermosensitive Liposome Formulated Indocyanine Green for Near-Infrared Triggered Photodynamic Therapy: In Vivo Evaluation for Triple-Negative Breast Cancer CS Shemesh, D Moshkelani, H Zhang Pharmaceutical Research 32, 1604-1614, 2015 | 65 | 2015 |
| Elucidation of the biotransformation pathways of a Galnac3-conjugated antisense oligonucleotide in rats and monkeys CS Shemesh, ZY Rosie, HJ Gaus, S Greenlee, N Post, K Schmidt, ... Molecular Therapy-Nucleic Acids 5, 2016 | 51 | 2016 |
| Near-infrared image-guided delivery and controlled release using optimized thermosensitive liposomes DC Turner, D Moshkelani, CS Shemesh, D Luc, H Zhang Pharmaceutical research 29, 2092-2103, 2012 | 48 | 2012 |
| Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer CS Shemesh, P Chanu, K Jamsen, R Wada, G Rossato, F Donaldson, ... Journal for ImmunoTherapy of Cancer 7, 1-13, 2019 | 38 | 2019 |
| Pharmacokinetic and pharmacodynamic investigations of ION-353382, a model antisense oligonucleotide: using alpha-2-macroglobulin and murinoglobulin double-knockout mice CS Shemesh, RZ Yu, HJ Gaus, PP Seth, EE Swayze, FC Bennett, ... Nucleic acid therapeutics 26 (4), 223-235, 2016 | 35 | 2016 |
| Pharmacology-based ranking of anti-cancer drugs to guide clinical development of cancer immunotherapy combinations V Lemaire, CS Shemesh, A Rotte Journal of Experimental & Clinical Cancer Research 40 (1), 311, 2021 | 34 | 2021 |
| Assessment of the drug interaction potential of unconjugated and GalNAc3-conjugated 2′-MOE-ASOs CS Shemesh, ZY Rosie, MS Warren, M Liu, M Jahic, B Nichols, N Post, ... Molecular Therapy-Nucleic Acids 9, 34-47, 2017 | 32 | 2017 |
| Integrated two‐analyte population pharmacokinetic model of polatuzumab vedotin in patients with non‐Hodgkin lymphoma D Lu, T Lu, L Gibiansky, X Li, C Li, P Agarwal, CS Shemesh, R Shi, ... CPT: Pharmacometrics & Systems Pharmacology 9 (1), 48-59, 2020 | 29 | 2020 |
| Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma CS Shemesh, P Agarwal, T Lu, C Lee, RC Dere, X Li, C Li, JY Jin, S Girish, ... Cancer chemotherapy and pharmacology 85, 831-842, 2020 | 14 | 2020 |
| Atezolizumab plus PEGPH20 versus chemotherapy in advanced pancreatic ductal adenocarcinoma and gastric cancer: MORPHEUS phase ib/II umbrella randomized study platform AH Ko, KP Kim, JT Siveke, CD Lopez, J Lacy, EM O’Reilly, T Macarulla, ... The Oncologist 28 (6), 553-e472, 2023 | 13 | 2023 |
| Atezolizumab and bevacizumab in patients with unresectable hepatocellular carcinoma: pharmacokinetic and safety assessments based on hepatic impairment status and geographic region CS Shemesh, P Chan, H Shao, DZ Xu, D Combs, S Vadhavkar, R Bruno, ... Liver Cancer 10 (5), 485-499, 2021 | 13 | 2021 |
| Assessment of the impact of anti-drug antibodies on PK and clinical outcomes with atezolizumab+ bevacizumab in HCC PR Galle, RS Finn, AL Cheng, CA Bernaards, P Chan, CS Shemesh, ... AACR Virtual Annual Meeting, 10-15, 2021 | 9 | 2021 |
| Pan‐cancer population pharmacokinetics and exposure‐safety and‐efficacy analyses of atezolizumab in patients with high tumor mutational burden CS Shemesh, P Chan, FA Legrand, DS Shames, M Das Thakur, J Shi, ... Pharmacology Research & Perspectives 8 (6), e00685, 2020 | 8 | 2020 |
| Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo)+ PEGPH20 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric … AH Ko, J Lee, M ALSINA, JA Ajani, YJ Bang, HC Chung, J Lacy, ... Journal of Clinical Oncology 38 (15_suppl), 4540-4540, 2020 | 8 | 2020 |
| Application of a two-analyte integrated population pharmacokinetic model to evaluate the impact of intrinsic and extrinsic factors on the pharmacokinetics of polatuzumab … D Lu, T Lu, R Shi, L Gibiansky, P Agarwal, CS Shemesh, RC Dere, ... Pharmaceutical Research 37, 1-16, 2020 | 7 | 2020 |
| Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo)+ BL-8040 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric … DY Oh, JA Ajani, YJ Bang, HC Chung, J Lacy, J Lee, T Macarulla, ... Journal of Clinical Oncology 38 (4_suppl), 712-712, 2020 | 7 | 2020 |
